Form 4: TOI CFO Robert Carter Executes Tax-Related Stock Sale
Statement of Changes in Beneficial Ownership
CFO Robert Carter sold 1,604 shares of The Oncology Institute, Inc. to satisfy tax obligations related to RSU vesting.
Summary
- Robert Carter, Chief Financial Officer of The Oncology Institute, Inc., disposed of 1,604 shares of common stock.
- The transaction occurred on May 21, 2026, at a price of $4.47 per share.
- The sale was executed to cover tax liabilities resulting from the vesting of a Restricted Stock Unit (RSU) award granted on May 21, 2024.
- Following this transaction, the reporting person maintains a beneficial ownership of 414,801 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax-related transaction rather than a strategic shift or market-driven divestment.
Positives
- The transaction was a mandatory sell-to-cover event for tax purposes rather than a discretionary divestment of equity.
Negatives
- Reduction in the direct equity stake held by the Chief Financial Officer.
Risks
- None identified; this is a routine administrative transaction related to tax compliance.
Future Outlook
No forward-looking guidance or strategic outlook provided in this filing.
Management Comments
- The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024.
Industry Context
StockSavvy.ai notes that sell-to-cover transactions are standard industry practice for executives to manage tax obligations upon the vesting of equity-based compensation and do not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for executive compensation tax withholding.
- The scale of the sale is immaterial relative to the total holdings of the reporting person.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a non-discretionary tax-related sale.
Next Steps
- None indicated.
Key Dates
| Date | Description |
|---|---|
| 05/21/2024 | Original grant date of the RSU award. |
| 05/21/2026 | Date of RSU vesting and subsequent tax-related share sale. |
| 05/22/2026 | Date of filing for the Form 4 statement. |
Keywords
TOI, The Oncology Institute, Insider Trading, Form 4, CFO, Equity Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.